维康药业(300878.SZ)发布前三季度业绩，归母净亏损1.24亿元

Core Viewpoint - Vicon Pharmaceutical (300878.SZ) reported a significant decline in revenue and increased net losses for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 151 million yuan, representing a year-on-year decrease of 59.20% [1] - The net loss attributable to shareholders of the listed company was 124 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 122 million yuan [1] - The basic loss per share was 0.8554 yuan [1]